RGLS Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Regulus Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$1.08 |
| Beta | 1.63 |
| 11 Month Change | 0.68% |
| 3 Month Change | -16.95% |
| 1 Year Change | 9.70% |
| 33 Year Change | -64.23% |
| 5 Year Change | -82.29% |
| Change since IPO | -99.71% |
Recent News & Updates
Recent updates
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Sep 28
Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Shareholder Returns
| RGLS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.8% | 2.4% | 2.2% |
| 1Y | 9.7% | 16.2% | 31.7% |
Return vs Industry: RGLS underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: RGLS underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| RGLS volatility | |
|---|---|
| RGLS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RGLS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RGLS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 32 | Jay Hagan | www.regulusrx.com |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. Fundamentals Summary
| RGLS fundamental statistics | |
|---|---|
| Market cap | US$91.70m |
| Earnings (TTM) | -US$41.63m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.3x
P/E RatioIs RGLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGLS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$22.62m |
| Gross Profit | -US$22.62m |
| Other Expenses | US$19.01m |
| Earnings | -US$41.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RGLS perform over the long term?
See historical performance and comparison